Table 1.
Infant Baseline Characteristics and Background Antiretrovirals (All Treated Infants)a
| Cohort 1 | Cohort 2 | |||||
|---|---|---|---|---|---|---|
| Stratum 1A N=8 (%) | Stratum 1B N=7 (%) | Total N=15 (%) | Stratum 2A N=16 (%) | Stratum 2B N=16 (%) | Total N=32 (%) | |
| Sex | ||||||
| Female | 5 (63) | 4 (57) | 9 (60) | 7 (44) | 7 (44) | 14 (44) |
| Male | 3 (38) | 3 (43) | 6 (40) | 9 (56) | 9 (56) | 18 (56) |
| Race | ||||||
| Asian | 0 (0) | 0 (0) | 0 (0) | 3 (19) | 0 (0) | 3 (9) |
| Black or African American | 5 (63) | 7 (100) | 12 (80) | 10 (63) | 16 (100) | 26 (81) |
| White | 3 (38) | 0 (0) | 3 (20) | 3 (19) | 0 (0) | 3 (9) |
| Gestational age (weeks) | ||||||
| Median | 38.5 | 39.0 | 39.0 | 39.0 | 40.0 | 39.0 |
| Q1,Q3b | 38.0,39.5 | 38.0,39.0 | 38.0,39.0 | 38.0,39.5 | 39.0,40.5 | 38.5,40.0 |
| Birth Weight (kg) | ||||||
| Median | 3.2 | 3.4 | 3.3 | 3.0 | 3.0 | 3.0 |
| Q1,Q3b | 2.8,3.5 | 2.9,3.6 | 2.9,3.5 | 2.9,3.2 | 2.8,3.2 | 2.8,3.2 |
| Background ARVs NRTI Only | ||||||
| 3TC, ZDV | 0 (0) | 0 (0) | 0 (0) | 1 (6) | 0 (0) | 1 (3) |
| ZDV | 7 (88) | 0 (0) | 7 (47) | 11 (69) | 0 (0) | 11 (34) |
| NNRTI(+/− NRTI) | ||||||
| 3TC, NVP, ZDV | 0 (0) | 0 (0) | 0 (0) | 3 (19) | 0 (0) | 3 (9) |
| NVP | 0 (0) | 7 (100) | 7 (47) | 0 (0) | 12 (75) | 12 (38) |
| NVP, ZDV | 1 (13) | 0 (0) | 1 (7) | 1 (6) | 4 (25) | 5 (16) |
a
ARV=antiretrovirals, NRTI=nucleoside reverse transcriptase inhibitor, NNRTI=non-nucleoside reverse transcriptase inhibitor, NVP=nevirapine, ZDV=zidovudine
b
Q1, Q3=25th and 75th percentiles, respectively